Metabolic syndrome severity score and the progression of CKD

• Published in: European journal of clinical investigation 2022-01, Vol.52 (1), p.e13646-n/a
• Main Authors: Wu, Mingyang, Shu, Yanling, Wang, Lulin, Song, Lulu, Chen, Shuohua, Liu, Yunyun, Bi, Jianing, Li, Dankang, Yang, Yingping, Hu, Yonghua, Wang, Youjie, Wu, Shouling, Tian, Yaohua
• Format: Article
• Language: English
• Subjects: Adult; chronic kidney disease; Cohort analysis; cohort study; Disease Progression; Epidermal growth factor receptors; Female; Humans; Kidney diseases; Male; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - diagnosis; metabolic syndrome severity; Middle Aged; progressive decline in renal function; Proteinuria; Renal function; Renal Insufficiency, Chronic - epidemiology; Renal Insufficiency, Chronic - etiology; Risk analysis; Risk Factors; Severity of Illness Index
• ISSN: 0014-2972; 1365-2362
• DOI: 10.1111/eci.13646

Background Metabolic syndrome severity, expressed by the continuous metabolic syndrome risk score (MetS score), has been demonstrated to be able to predict future health conditions. However, little is known about the association between MetS score and renal function. Methods A total of 22,719 participants with normal renal function ed from the Kailuan Study were followed from 2006 to 2016. The new onset of chronic kidney disease (CKD) was defined as eGFR 300 mg/dl. Progressive decline in renal function was defined as an annual change rate of eGFR below the 10th percentile of the whole population. Results In the multivariate‐adjusted model, we found that the risk of progressive decline in renal function increased consistently with the MetS score, with an odds ratio of 1.49 (95% CI, 1.28, 1.73) for those subjects>75th percentile compared with those 75th percentile compared with those